ReviewMini reviews in medicinal chemistry2026
Targeting Chemical-induced Hepatocellular Carcinoma: Ameliorative Potential of Natural Compounds with Focus on Beta-carbolines.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionHepatocellular carcinoma (HCC), the predominant form of primary liver malignancy, remains a major global health concern owing to its aggressive progression, limited therapeutic efficacy, and high fatality rate. A significant proportion of HCC arises from chronic exposure to chemical carcinogens, which trigger hepatocarcinogenesis through oxidative stress, DNA damage, and dysregulation of signalling networks. Natural compounds, particularly beta-carboline alkaloids, are emerging as safer, multi-targeted candidates with promising hepatoprotective and anticancer potential. This review has critically evaluated chemical-induced hepatocarcinogenesis and the therapeutic relevance of beta-carbolines in HCC.
methodsA systematic literature survey was conducted using PubMed, Scopus, and Web of Science databases, emphasizing studies on chemical-induced HCC, natural hepatoprotective compounds, and beta-carboline derivatives. Mechanistic, pharmacological, and preclinical data were extracted and analyzed.
resultsCarcinogens, such as diethylnitrosamine (DEN), aflatoxin B1, and carbon tetrachloride (CCl DISCUSSION: The accumulating evidence highlights beta-carbolines as versatile natural agents with multi-faceted mechanisms against chemical-induced hepatocarcinogenesis. Nonetheless, gaps remain in understanding their pharmacokinetics, bioavailability, and long-term safety. Preclinical data are encouraging, but translational studies and clinical validations are limited, underscoring the need for further research.
conclusionBeta-carboline alkaloids hold significant promise as therapeutic candidates for chemical- induced HCC. Addressing challenges related to safety, bioavailability, and clinical applicability can prove to be crucial for their future development.
Indexed as
Identifiers
41088942What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.